Cabaletta Bio, Inc. (CABA)

Cabaletta Bio's stock (CABA) has increased significantly, with a 72.90% change over the past year. Insider buying in January 2026 led to a stock price increase. Discussions around the RESET program generated optimism. Q4 and full year 2025 financial results highlighted progress in clinical programs and a strong cash position. Analysts have issued positive ratings with a median price target of $16.0. Q3 2025 financial results provided updates on rese-cel data and its safety profile.

As a clinical-stage biotechnology company, Cabaletta Bio, Inc. does not have traditional demand seasonality. The demand for its offerings is primarily related to patient enrollment in clinical trials and the progress of its drug development pipeline, driven by factors such as the prevalence of targeted autoimmune diseases and clinical development timelines.

Cabaletta Bio, Inc. is a clinical-stage biotechnology company focused on developing engineered T cell therapies for autoimmune diseases. The company's CABA™ platform uses CARTA and CAART strategies to develop curative treatments. The lead product candidate, rese-cel, is being evaluated in the RESET™ clinical development program for various autoimmune diseases. Other key clinical-stage candidates include DSG3-CAART for mucosal pemphigus vulgaris and MuSK-CAART for anti-muscle-specific kinase antibody positive myasthenia gravis.

Cabaletta Bio, Inc. is headquartered and maintains laboratory facilities in Philadelphia, Pennsylvania, United States.

Cabaletta Bio's reputation has been influenced by physician enthusiasm due to promising clinical data and positive sentiment from insider buying and clinical progress in its RESET program. The company's focus on addressing unmet medical needs in autoimmune diseases also contributes positively to its reputation. Investor skepticism was noted in September 2025, despite positive clinical data, and the inherent risks of a clinical-stage biotechnology company can contribute to investor caution.

Cabaletta Bio, Inc. is primarily owned by institutional shareholders, who hold 68.49% of the stock, insiders own 3.91%, and retail investors hold 27.60%. Major institutional owners include T. Rowe Price Investment Management, Inc., Bain Capital Life Sciences Investors, LLC, and Jennison Associates Llc. James E. Flynn is the largest individual shareholder, owning 1.46% of the company, and the CEO, Steven Nichtberger, holds 1.4% of the shares.